title: Incidence of bleeding complications associated with abciximab use in conjunction with thrombolytic therapy in patients requiring percutaneous transluminal coronary angioplasty.
abstract: The use of abciximab after full-dose failed thrombolytics within 15 hours of acute myocardial infarction significantly increases the risk of major bleeding complications.
authors.affiliation: Division of Cardiovascular Medicine, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA.
authors.forename: D W
authors.initials: DW
authors.lastname: Sundlof
authors.forename: P
authors.initials: P
authors.lastname: Rerkpattanapitat
authors.forename: N
authors.initials: N
authors.lastname: Wongpraparut
authors.forename: P
authors.initials: P
authors.lastname: Pathi
authors.forename: M N
authors.initials: MN
authors.lastname: Kotler
authors.forename: L E
authors.initials: LE
authors.lastname: Jacobs
authors.forename: G S
authors.initials: GS
authors.lastname: Ledley
authors.forename: S
authors.initials: S
authors.lastname: Yazdanfar
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012189:Retrospective Studies; D015912:Thrombolytic Therapy
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab